Enrolling by invitationPriority 4 · Lower priorityNCT07450040

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma

Plain-language summary

This study is studying a new treatment for people with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

Age 18 Years to 70 Years years
Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Drugs / treatments
Treatment length: Ask the trial team for details
Visit frequency: Ask the trial team for details

TrialCompass — Clinical Trial Summary

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma

NCT07450040

Status: Enrolling by invitation | Priority: Lower

Plain-language summary

This study is studying a new treatment for people with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

Age 18 Years to 70 Years years
Must be well enough for treatment (adequate performance status)

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 60 patients

Primary endpoint: ORR

Ages: 18 Years to 70 Years

Start date: 2024-09-12 | Est. completion: 2027-12-31

Locations

0 US sites · 1 total

Contact

—

Sponsor: Eye & ENT Hospital of Fudan University (OTHER)

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07450040

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.